New Delhi: Danish pharma giant Novo Nordisk has introduced its diabetes drug Ozempic in the Indian market, and this is likely to strengthen the country’s fight against type-2 diabetes. The company announced on Friday that the weekly starting dose will cost Rs 2,200 for the 0.25 mg version, making India one of the latest countries to gain access to the globally popular semaglutide injection.

Ozempic will be sold in India in three strengths — 0.25 mg, 0.5 mg, and 1 mg — all supplied in single-use, pre-filled pens fitted with Novofine needles. These pens are designed to deliver a painless, under-the-skin injection, something many patients appreciate when transitioning to injectable therapy.

Doctors typically begin patients on 0.25 mg once a week for the first month. After the introductory

See Full Page